AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22854110 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic dissection
Number of subjects: 60
Study 20370727 — intervention group
Group type: EXPERIMENTAL
Intervention: Yun-chang capsule 70 mg plus placebo 35 mg (group A)
Number of subjects: 132
Study 20370727 — intervention group
Group type: EXPERIMENTAL
Intervention: Yun-chang capsule 105 mg (group B)
Number of subjects: 132
Study 20370727 — intervention group
Group type: COMPARATOR
Intervention: Placebo 105 mg (group C)
Number of subjects: 132
Study 17646514 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical EMLA cream 60 min before block plus 2 mL IV normal saline 5 min before procedure
Number of subjects: 60
Study 17646514 — intervention group
Group type: COMPARATOR
Intervention: Topical sham cream plus 2 mL IV normal saline
Number of subjects: 60
Study 17646514 — intervention group
Group type: COMPARATOR
Intervention: Topical sham cream plus 0.1 microg/kg of sufentanil in 2 mL solution IV
Number of subjects: 60
Study 17646514 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pain for the whole procedure
Number of subjects: 60
Study 16114181 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanillin treatment
Number of subjects: 30
Study 16114181 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30
Study 12893953 — intervention group
Group type: EXPERIMENTAL
Intervention: tissue plasminogen activator
Number of subjects: 35
Study 12893953 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 35
Study 11172795 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 80
Study 11172795 — intervention group
Group type: COMPARATOR
Intervention: Norplant
Number of subjects: 80
Study 9051777 — intervention group
Group type: EXPERIMENTAL
Intervention: Coherent and meaningful objects
Number of subjects: 0
Study 9051777 — intervention group
Group type: COMPARATOR
Intervention: Disorganized and meaningless non-objects
Number of subjects: 0
Study 2066644 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose octreotide (200 micrograms)
Number of subjects: 9
Study 2066644 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose octreotide (400 micrograms)
Number of subjects: 9
Study 2066644 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide infusion (both doses)
Number of subjects: 9
Study 2066644 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline solution)
Number of subjects: 9
Study 6646402 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of lorazepam (Ativan)
Number of subjects: 16
Study 6646402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30842166 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted thoracoscopic esophagectomy (RATE)
Number of subjects: 59
Study 30842166 — intervention group
Group type: COMPARATOR
Intervention: Conventional thoracoscopic esophagectomy (TE)
Number of subjects: 59
Study 28962602 — intervention group
Group type: EXPERIMENTAL
Intervention: SDT‐WL (Self-Determination Theory-based Weight Loss Treatment)
Number of subjects: 64
Study 28962602 — intervention group
Group type: COMPARATOR
Intervention: BWL (Standard Behavioral Weight Loss Treatment)
Number of subjects: 64
Study 25811932 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive fitting process
Number of subjects: 40
Study 25811932 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic fitting process
Number of subjects: 40
Study 23576409 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted examination
Number of subjects: 60
Study 22054524 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford House (OH)
Number of subjects: 129
Study 22054524 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 129
Study 19270762 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS over the left DLPFC for 2 weeks
Number of subjects: 0
Study 19270762 — intervention group
Group type: EXPERIMENTAL
Intervention: Single session of rTMS over the left DLPFC
Number of subjects: 0
Study 19270762 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (placebo control)
Number of subjects: 0
Study 17261395 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐pro‐BNP levels at 12 to 24 hours after PCI
Number of subjects: 747
Study 17261395 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐pro‐BNP increase in patients with periprocedural MI
Number of subjects: 747
Study 17261395 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐pro‐BNP correlation with extent of myocardial injury
Number of subjects: 747
Study 15016048 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (3-5 microg/kg/min) for 48 hours
Number of subjects: 85
Study 12324552 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (INR 2.8 to 4.2)
Number of subjects: 3630
Study 12324552 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (160 mg daily)
Number of subjects: 3630
Study 12324552 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (INR 2.0 to 2.5) and Aspirin (75 mg daily)
Number of subjects: 3630
Study 12324552 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (both dosages)
Number of subjects: 3630
Study 10589612 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) - IV infusion of 15 mg/kg over 30 min, followed by 10 mg x kg(‐1) x hr(‐1) for 12 hours
Number of subjects: 40
Study 10589612 — intervention group
Group type: COMPARATOR
Intervention: Normovolemic hemodilution (NVHD) - blood removed to target hematocrit of approximately 28%, maintained with lactated Ringer's solution
Number of subjects: 40
Study 8755835 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone hydrochloride
Number of subjects: 237
Study 1862210 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg oral test dose of haloperidol (HPDL)
Number of subjects: 28
Study 1862210 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirically determined doses of HPDL (2, 4, or 10 mg b.i.d.)
Number of subjects: 28
Study 1862210 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour log plasma level
Number of subjects: 28
Study 1862210 — intervention group
Group type: EXPERIMENTAL
Intervention: Final Css
Number of subjects: 28
Study 6358487 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 0
Study 6358487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30661255 — intervention group
Group type: EXPERIMENTAL
Intervention: cilofexor 100 mg
Number of subjects: 52
Study 30661255 — intervention group
Group type: EXPERIMENTAL
Intervention: cilofexor 30 mg
Number of subjects: 52
Study 30661255 — intervention group
Group type: COMPARATOR
Intervention: cilofexor placebo
Number of subjects: 52
Study 29422080 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Number of subjects: 753
Study 27307717 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced Retrieval (SR) training
Number of subjects: 140
Study 27307717 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced Retrieval (SR) training combined with Montessori activities (SR + M)
Number of subjects: 140
Study 27307717 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study 24756766 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin), a catecholamine reuptake blocker, dosage and duration not specified
Number of subjects: 0
Study 24756766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23357414 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 543
Study 23357414 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 543
Study 20716243 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics prescribed
Number of subjects: 5640
Study 20716243 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics prescribed
Number of subjects: 5640
Study 17923388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention for children with autism
Number of subjects: 81
Study 17923388 — intervention group
Group type: COMPARATOR
Intervention: Control group (children with developmental disabilities)
Number of subjects: 81
Study 15915401 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate (0.10 mg/kg)
Number of subjects: 45
Study 15915401 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.035 mg/kg)
Number of subjects: 45
Study 12659466 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (25 g daily for 6 weeks)
Number of subjects: 24
Study 12659466 — intervention group
Group type: COMPARATOR
Intervention: Placebo (mild protein)
Number of subjects: 24
Study 12659466 — intervention group
Group type: COMPARATOR
Intervention: Soy protein and Placebo
Number of subjects: 24
Study 10388961 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood Glucose Awareness Training (BGAT)
Number of subjects: 47
Study 10388961 — intervention group
Group type: COMPARATOR
Intervention: Cholesterol Awareness (Control)
Number of subjects: 47
Study 8602665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane in air/oxygen 30% (n = 40)
Number of subjects: 120
Study 8602665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane in 70% N2O/30% O2 (n = 40)
Number of subjects: 120
Study 8602665 — intervention group
Group type: COMPARATOR
Intervention: Halothane in 70% N2O/30% O2 (n = 40)
Number of subjects: 120
Study 1315092 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin A1
Number of subjects: 30
Study 1315092 — intervention group
Group type: COMPARATOR
Intervention: Dextrose 5% (placebo)
Number of subjects: 30
Study 1315092 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin A1 (in normotensive subjects)
Number of subjects: 30
Study 3907987 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam plus pivampicillin (200 mg pivmecillinam plus 250 mg pivampicillin)
Number of subjects: 318
Study 3907987 — intervention group
Group type: COMPARATOR
Intervention: co-trimoxazole (800 mg sulphamethoxazole plus 160 mg trimethoprim)
Number of subjects: 318
Study 3907987 — intervention group
Group type: EXPERIMENTAL
Intervention: pivmecillinam plus pivampicillin
Number of subjects: 318
Study 3907987 — intervention group
Group type: COMPARATOR
Intervention: co-trimoxazole
Number of subjects: 318
Study 30101646 — intervention group
Group type: EXPERIMENTAL
Intervention: Fist Assist® device (intermittent pneumatic compression) worn 6 hours daily for 30 days.
Number of subjects: 59
Study 30101646 — intervention group
Group type: COMPARATOR
Intervention: Sham device (control group).
Number of subjects: 59
Study 29529606 — intervention group
Group type: EXPERIMENTAL
Intervention: Music played during surgery (group M)
Number of subjects: 50
Study 29529606 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 50
Study 26478225 — intervention group
Group type: EXPERIMENTAL
Intervention: TPTD 56.5 μg
Number of subjects: 290
Study 26478225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 23032083 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) 2700 mg/day from day after surgery until day 30
Number of subjects: 162
Study 23032083 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EPA)
Number of subjects: 162
Study 22777865 — intervention group
Group type: EXPERIMENTAL
Intervention: ODN 50 mg
Number of subjects: 100
Study 22777865 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after switching from ODN 50 mg)
Number of subjects: 100
Study 22777865 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ODN (10-50 mg)
Number of subjects: 100
Study 22777865 — intervention group
Group type: COMPARATOR
Intervention: Switched from ODN (10-50 mg) to placebo after 2 years
Number of subjects: 100
Study 22777865 — intervention group
Group type: EXPERIMENTAL
Intervention: ODN (10-50 mg) for 5 years
Number of subjects: 100
Study 22777865 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of ODN
Number of subjects: 100
Study 19709169 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy treatment for cancer
Number of subjects: 0
Study 19709169 — intervention group
Group type: COMPARATOR
Intervention: Matched individuals who did not have cancer
Number of subjects: 0
Study 19709169 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of chemotherapy-treated adults
Number of subjects: 0
Study 18695053 — intervention group
Group type: EXPERIMENTAL
Intervention: LY450139 (100 mg)
Number of subjects: 51
Study 18695053 — intervention group
Group type: EXPERIMENTAL
Intervention: LY450139 (140 mg)
Number of subjects: 51
Study 18695053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 15923270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ilioinguinal/iliohypogastric nerve block using levobupivacaine 0.25%
Number of subjects: 100
Study 15923270 — intervention group
Group type: COMPARATOR
Intervention: Conventional 'fascial click' method using levobupivacaine 0.25% (0.3 ml kg(‐1))
Number of subjects: 100
Study 15923270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided ilioinguinal/iliohypogastric nerve block
Number of subjects: 100
Study 15923270 — intervention group
Group type: COMPARATOR
Intervention: Conventional 'fascial click' method
Number of subjects: 100
Study 12587886 — intervention group
Group type: EXPERIMENTAL
Intervention: one‐skate (V2)
Number of subjects: 12
Study 12587886 — intervention group
Group type: EXPERIMENTAL
Intervention: offset (V1)
Number of subjects: 12
Study 12587886 — intervention group
Group type: EXPERIMENTAL
Intervention: conventional
Number of subjects: 12
Study 12587886 — intervention group
Group type: EXPERIMENTAL
Intervention: two‐skate (V2A)
Number of subjects: 12
Study 10553847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 2.5 microg sufentanil, 1.25 mg bupivacaine, 25 microg epinephrine
Number of subjects: 105
Study 10553847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal 5 microg sufentanil, 1.25 mg bupivacaine, 25 microg epinephrine
Number of subjects: 105
Study 10553847 — intervention group
Group type: COMPARATOR
Intervention: Control group: 1.25 mg bupivacaine, 25 microg epinephrine
Number of subjects: 105
Study 8994513 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 18
Study 8994513 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium metabisulphite (MBS)
Number of subjects: 18
Study 8214455 — intervention group
Group type: EXPERIMENTAL
Intervention: New design of tracheal tube with a tapered tip, without a bevel
Number of subjects: 60
Study 8214455 — intervention group
Group type: COMPARATOR
Intervention: Standard design tracheal tube
Number of subjects: 60
Study 3306597 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP (polyribosyl ribitol phosphate)
Number of subjects: 94
Study 3306597 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP-D (PRP covalently linked to diphtheria toxoid)
Number of subjects: 94
Study 28984091 — intervention group
Group type: EXPERIMENTAL
Intervention: ARM+ZEEP group (repeated ARMs every 30 minutes without extra PEEP)
Number of subjects: 36
Study 28984091 — intervention group
Group type: EXPERIMENTAL
Intervention: ARM+PEEP group (ARMs followed by 8 cmH2O of PEEP)
Number of subjects: 36
Study 28984091 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intraoperative ARMs)
Number of subjects: 36
Study 26192386 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior activation therapy
Number of subjects: 75
Study 26070195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR) for 12 weeks (n=18)
Number of subjects: 46
Study 26070195 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST) for 12 weeks (n=22)
Number of subjects: 46
Study 23515409 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Zoledronic Acid (ZOL)
Number of subjects: 40
Study 23515409 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 40
Study 21592633 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lignocaine hydrochloride with adrenaline 1:80,000 plus 8.4% sodium bicarbonate in a 1/10 dilution
Number of subjects: 100
Study 19802403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (iv) outpatient treatment with amikacin or ceftriaxona, followed by oral antimicrobial after urine culture results, duration of iv treatment 2.9 days (SD 1.9)
Number of subjects: 112
Study 19802403 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (iv) inpatient treatment with amikacin or ceftriaxona, followed by oral antimicrobial after urine culture results, duration of iv treatment 2.8 days (SD 1.2)
Number of subjects: 112
Study 17113895 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased fluid intake (1.5 L of extra water daily)
Number of subjects: 141
Study 17113895 — intervention group
Group type: COMPARATOR
Intervention: Placebo (one tablespoon of placebo syrup daily)
Number of subjects: 141
Study 15555817 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset cannabis use (females)
Number of subjects: 2311
Study 15555817 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset inhalant use (females)
Number of subjects: 2311
Study 15555817 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-onset alcohol and tobacco use
Number of subjects: 2311
Study 11349839 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg of levothyroxine
Number of subjects: 24
Study 11349839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10776821 — intervention group
Group type: EXPERIMENTAL
Intervention: Servo-controller of heart rate using a cycle ergometer at 60% of age-predicted maximum HR
Number of subjects: 55
Study 10776821 — intervention group
Group type: EXPERIMENTAL
Intervention: Servo-controller of heart rate using a cycle ergometer at 75% of age-predicted maximum HR
Number of subjects: 55
Study 8087329 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) 200 micrograms twice per day for 2 weeks
Number of subjects: 12
Study 8087329 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD) 200 micrograms twice per day for 2 weeks
Number of subjects: 12
Study 2676000 — intervention group
Group type: EXPERIMENTAL
Intervention: (2"R)-4'-O-tetrahydropyranyladriamycin (THP) in combination with 5-fluorouracil (5-FU) and cyclophosphamide (CPA)
Number of subjects: 64
Study 2676000 — intervention group
Group type: COMPARATOR
Intervention: Adriamycin (ADR) in combination with 5-fluorouracil (5-FU) and cyclophosphamide (CPA)
Number of subjects: 64
Study 2676000 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival duration
Number of subjects: 64
Study 2676000 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 64
Study 1097978 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylocain‐Exadrin 2%
Number of subjects: 379
Study 1097978 — intervention group
Group type: COMPARATOR
Intervention: Citanest‐Octopressin 3%
Number of subjects: 379
Study 30858039 — intervention group
Group type: EXPERIMENTAL
Intervention: Podcasts
Number of subjects: 84
Study 30858039 — intervention group
Group type: EXPERIMENTAL
Intervention: Text chapters
Number of subjects: 84
Study 30858039 — intervention group
Group type: COMPARATOR
Intervention: UCS participants
Number of subjects: 84
Study 30858039 — intervention group
Group type: COMPARATOR
Intervention: RCT participants
Number of subjects: 84
Study 27736689 — intervention group
Group type: EXPERIMENTAL
Intervention: naltrexone 1mg b.i.d.
Number of subjects: 12
Study 27736689 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 24428375 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 65335
Study 24428375 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 65335
Study 24428375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty
Number of subjects: 65335
Study 24428375 — intervention group
Group type: COMPARATOR
Intervention: Uncemented hemiarthroplasty
Number of subjects: 65335
Study 23948131 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 64
Study 23948131 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 64
Study 20144218 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training programme for healthcare professionals
Number of subjects: 700
Study 17707693 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐40% ECC (10% of maximal isometric strength)
Number of subjects: 18
Study 17707693 — intervention group
Group type: COMPARATOR
Intervention: 40% ECC
Number of subjects: 18
Study 16702135 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12932592 — intervention group
Group type: EXPERIMENTAL
Intervention: AF Suppression Algorithm (treatment group)
Number of subjects: 0
Study 12932592 — intervention group
Group type: COMPARATOR
Intervention: Control group (algorithm off)
Number of subjects: 0
Study 11231208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and typhoid fever vaccine (25 microg typhoid Vi polysaccharide and at least 1,440 ELISA units of inactivated hepatitis A in a 1 mL dose)
Number of subjects: 462
Study 11231208 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and typhoid fever vaccine
Number of subjects: 462
Study 2221314 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fentanyl (0.05 mg/kg) and pancuronium (0.1 mg/kg)
Number of subjects: 8
Study 2221314 — intervention group
Group type: COMPARATOR
Intervention: Balanced anesthesia with 0.02 mg/kg flunitrazepam, N2O/O2 1:1, isoflurane 0.5 vol%, and pancuronium (0.1 mg/kg) with a bolus of 0.005 mg/kg fentanyl
Number of subjects: 8
Study 284708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfaphenazole
Number of subjects: 0
Study 284708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadiazine
Number of subjects: 0
Study 284708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethiazole
Number of subjects: 0
Study 284708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole + Trimethoprim
Number of subjects: 0
Study 284708 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim
Number of subjects: 0
Study 284708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole
Number of subjects: 0
Study 284708 — intervention group
Group type: COMPARATOR
Intervention: Sulfamethoxypyridazine
Number of subjects: 0
Study 284708 — intervention group
Group type: COMPARATOR
Intervention: Sulfadimethoxine
Number of subjects: 0
Study 284708 — intervention group
Group type: COMPARATOR
Intervention: Sulfamethoxydiazine
Number of subjects: 0